Explore the Australian Prescriber issue: Volume 47 Issue 6.

The December edition of Australian Prescriber covers the timely topic of therapeutic use of vapes for smoking cessation and nicotine dependence. Practical advice is provided on assessing suitability, and initiating and ceasing use, framed in the context of the recent legislative reforms and updated clinical guidelines.

Also included are articles on the diagnosis and management of antiphospholipid syndrome, and the impact and importance of adverse drug reaction reporting to the Therapeutic Goods Administration. An editorial supporting the new Clinical Care Standard on chronic obstructive pulmonary disease (COPD) highlights the opportunity to improve the diagnosis and management of this condition in Australia.

Don’t miss our annual top 10 drugs feature and, as always, the comments on new drugs marketed in Australia.

Explore the December issue:

• Therapeutic vapes for smoking cessation and nicotine dependence
• Diagnosis and management of antiphospholipid syndrome
• Pharmacovigilance in Australia: how do adverse event reports from clinicians contribute to medicine and vaccine safety?
• Establishing a national standard to achieve better health outcomes for people living with COPD
• Acute tacrolimus toxicity due to concomitant use of ritonavir (with nirmatrelvir as Paxlovid)
• Oral health impacts of vaping
• Top 10 drugs 2023–24

New drugs:

• Deucravacitinib for plaque psoriasis
• Icosapent ethyl for reduction in the risk of cardiovascular events in adults with elevated triglycerides

As we reflect on 2024, we want to thank all our authors, peer reviewers and our wonderful readers! Enjoy your holiday season. See you in 2025!

The next Australian Prescriber Podcast episode will be released on 07 January 2025. In February 2025, a special edition of the Australian Prescriber journal will hit the website. It's our 50-year anniversary so look out for a mega issue coming your way in February next year!

Subscribe to get the latest articles and podcast episodes for free.